Rezilta esè vaksen kont grip COVID-19 yo disponib kounye a

Avril 20, 2022
by Linda Hohnholz
Li min li
A HOLD FreeRelease 3 | eTurboNews | eTN
Ekri pa Linda Hohnholz

Novavax, Inc. today announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination Vaccine (CIC). The CIC combines Novavax’ COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate. The CIC trial demonstrated that formulating the combination vaccine is feasible, well-tolerated and immunogenic.             “We continue to evaluate the dynamic public health landscape and…

eTurboNews atik yo se pou abonnés sèlman. Abònman se GRATIS.
Abonnés konekte isit la Klike la a pou w abònman GRATIS

KISA POU RETIRE NAN ATIK SA A:

  • The CIC trial demonstrated that formulating the combination vaccine is feasible, well-tolerated and immunogenic.
  • today announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination Vaccine (CIC).
  • The CIC combines Novavax’.
Ekri an lèt detacheLinkedInTelegramWhatsAppVKMessengerSMSRedditFlipboardPinteresttumblrXingTanponNouvèl piratèliyMelanjePòchYummlyKopi

<

Ou tou ka renmen

Sou otè a

Linda Hohnholz

Editè an chèf pou eTurboNews ki baze nan HQ eTN.

Wè tout posts
Pataje pou...
TanponKopiFlipboardNouvèl piratèliyLinkedInMessengerMelanjePinterestPòchEkri an lèt detacheRedditSMSTelegramtumblrVKWhatsAppXing